



1 / 41

Fig.
1



2 / 41


Fig.
2



3 / 41

Fig. 3


3



4 / 41


Fig.

4




5 / 41

Fig.
5



6 / 41


Fig.
6




7 / 41

Fig.

7





9 / 41

Fig.

9





Fig.

10




11 / 41

Fig.

11

Vector name
ベクター名



相对活性值 (%)

Relative activity

12 / 41

Fig

12






Fig.

13




☒ 14



14 / 41

Fig.


15



15 / 41


Fig. 16

16



16 / 41



Fig.
17



17 / 41

Fig.



18



18 / 41


fig

19



19 / 41


Fig.
20



20 / 41

Fig.


21



21 / 41

Fig.

22



22 / 41

Fig.

23




Fig.
24






Fig.
25



24 / 41

Fig.

26




結合活性 (OD415)


Binding activity

25 / 41

Fig.

☒ 27


cell
G361細胞



26 / 41

Fig.

28




27 / 41

fig.

29

Cytotoxic activity
細胞障害活性(%)



28 / 41

Fig.

30






Fig.

3 1




3 2



30 / 41

Fig.

~~33~~ 33





結合活性(OD415)

Binding activity



31 / 41

Fig.
3 4

Cell
G361細胞




Cell
SK-MEL-28細胞



32 / 41

Fig.

35



33 / 41

Fig

~~36~~






Fig.
37



35 / 41


Fig.

38




B16 · F10 (親株)

Parent strain



B16 - 29-10




B16 - 8-3

36 / 41

Fig.

39




バーは各群の平均値

Bar: Average value of each group

37 / 41

Fig.

~~40~~ 40




バーは各群の平均値

Bar: Average value of each group

Fig.

~~41~~ 41



バーは各群の平均値

Bar: Average value of each group

No administration

○ KM871-nIL-2

● KM871+hIL-2 倍用投与

Combined administration

38 / 41

Fig.

42

Tumor volume of each group
/ tumor volume of non-administered group





Fig. 43

v/v0 of each group
/ v/v0 of non-administered group




39 / 41

Fig.

~~☒~~ 44

各群の非投与群のVVO / 各群の投与群のVVO

~~投与開始後の目数~~

Days after administration started

.....~~コントロール~~ Control
~~ビル~~ = ?

—▲— hIL-2
—●— KM87


—●— KM871
—●— KM871+KM871-hIL-2 15 μ g ~~并用~~ Combined use

—◆— KM871+KM871 — hIL-2 80μg ~~使用~~ Combined use

40 / 41


Fig

45



46

Fig.



41 / 41

Fig.

47





Fig.

48



縦軸: 転移巣の数 バー: 各群の平均値
グラフ中の数値: KM871-hIL-2投与による転移阻害率

Ordinate: number of metastatic foci

Bar: average of each group

Value in the graph: metastasis inhibition ratio by KM871-hIL-2 administration